Tolebrutinib was found to delay disability progression in people with nonrelapsing secondary progressive MS in a Phase 3 ...

Treatment with CNM-Au8 led to clinical improvements in relapsing-remitting MS patients that linked to signs of nerve cell ...

Getting used to living with MS is like trying to cook in a kitchen that's unfamiliar, columnist Ben Hofmeister writes.

The Phase 4 ENABLE study is set to be first in the U.S. to collect real-world safety and efficacy data of Briumvi for ...

A new artificial intelligence (AI) tool called MindGlide was found to accurately calculate MS-related brain damage using a ...

Nondrug therapy costs for people with MS in Austria can be high, averaging €136 per month (about $149), according to a study.

Columnist Desiree Lama shares what she wishes she'd been told after her diagnosis of multiple sclerosis at age 17.